Janney Montgomery Scott LLC Trims Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Janney Montgomery Scott LLC lowered its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 6.0% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,266 shares of the specialty pharmaceutical company’s stock after selling 656 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Jazz Pharmaceuticals were worth $1,144,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the period. Itau Unibanco Holding S.A. purchased a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth $29,000. EverSource Wealth Advisors LLC lifted its stake in shares of Jazz Pharmaceuticals by 55.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 97 shares during the period. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares during the period. Finally, Gladius Capital Management LP purchased a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth $33,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.1 %

Shares of Jazz Pharmaceuticals stock opened at $121.65 on Friday. The business has a 50-day moving average of $112.22 and a 200-day moving average of $110.35. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The company has a market capitalization of $7.35 billion, a PE ratio of 17.13, a P/E/G ratio of 1.07 and a beta of 0.57. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $134.17.

Insider Activity

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total transaction of $110,840.00. Following the transaction, the chief executive officer now owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Mary Elizabeth Henderson sold 1,410 shares of the stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at $1,573,707.30. The trade was a 8.85 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 6,110 shares of company stock worth $720,160 over the last ninety days. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on JAZZ shares. JPMorgan Chase & Co. increased their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $140.00 target price on shares of Jazz Pharmaceuticals in a research report on Monday, September 9th. Wells Fargo & Company cut their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and issued a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Finally, Royal Bank of Canada increased their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $175.00.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.